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Background: Autoimmune thrombocytopenic purpura is an immunological disorder characterized by increased
platelet destruction due to presence of anti-platelet autoantibodies. Hepatitis C virus infection, which is one of the
most common chronic viral infections worldwide, may cause secondary chronic immune thrombocytopenic
purpura.
Case presentation: We report a case of a 51-year-old Caucasian female with hepatitis C virus infection who
developed a severe, reversible, immune thrombocytopenia. Platelet count was as low as 56.000/mm3, hepatitis C
virus serology was positive, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase and
gamma-glutamyltransferase serum levels were elevated. Disorders potentially associated with autoimmune
thrombocytopenic purpura were ruled out. A corticosteroid treatment was started and led to an increase in platelet
count. The patient was then treated with pegylated-interferon alpha 2a and ribavirin. After four weeks of treatment
hepatitis C virus - ribonucleic acid became undetectable and steroid treatment was discontinued. Six months of
antiviral therapy achieved a sustained biochemical and virological response together with persistence of normal
platelet count.
Conclusion: In our case report hepatitis C virus seemed to play a pathogenic role in autoimmune
thrombocytopenic purpura. Moreover, the successful response (negative hepatitis C virus - ribonucleic acid) to
tapered steroids and antiviral therapy was useful to revert thrombocytopenia.
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Autoimmune thrombocytopenic purpura (AITP) is an im-
munological disorder characterized by increased platelet
destruction due to presence of anti-platelet autoantibodies
[1]. The resulting thrombocytopenia may expose patients
to life – threatening hemorrhagic complications. AITP
has been classified either as a primary autoimmune dis-
order or as secondary to a number of underlying condi-
tions such as lymphoproliferative disorders, myelodysplasia,
autoimmune collagen vascular diseases (e.g., systemic lupus
erythematosus, antiphospholipid antibody syndrome) liver
disease with portal hypertension, drugs or viral infection.
Thrombocytopenia has also been described in association
with hepatitis C virus (HCV) which is one of the most
common chronic viral infections worldwide and a major* Correspondence: mpersico@unisa.it
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reproduction in any medium, provided the orcause of cirrhosis, end-stage liver disease, and hepatocellu-
lar carcinoma [2,3]. The pathophysiology of thrombocy-
topenia in patients with HCV chronic infection is complex
and multifactorial [4,5]. However, pathogenic mechanisms
may include: hypersplenism secondary to portal hyperten-
sion when patients develop extensive fibrosis and/or cir-
rhosis, bone marrow suppression resulting from either
HCV itself or interferon treatment, thrombopoietin (TPO)
deficiency secondary to liver dysfunction and aberrations
of the immune system resulting in the formation of anti-
platelet antibodies and/or immunocomplexes that bind to
platelets and facilitate their premature clearance. The
most common target antigens for anti-platelet antibodies
are glycoprotein IIb/IIIa, followed by GP IIIa, GP IIb, GP
Ib then GP Ia [6]. A high prevalence of anti-HCV anti-
bodies has recently been reported in a series of patients
with AITP [7,8] and several cases of AITP have been re-
ported in patients with chronic hepatitis C [9]. Therefore
it is likely that HCV may play a role in the pathogenesis ofLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ment with pegylated-interferon and ribavirin, which could
be associated with a number of adverse events. The most
frequently observed side effects are hematological and re-
quire dose reduction or treatment cessation. Autoimmune
thrombocytopenia, thrombotic thrombocytopenic purpura
and autoimmune hemolytic anemia have been observed in
association with PEG-interferon use [8,10-16].
We report the case of a 51 - year – old Caucasian female
who developed a severe, reversible, immune thrombocy-
topenia associated with hepatitis C virus infection. We
described also our treatment schedule tapering simul-
taneously steroids and standard antiviral therapy with
pegylated-interferon - alpha 2a (PEG-IFN – α 2a) and
ribavirin on the basis of platelet count and hepatitis C
virus - ribonucleic acid (HCV-RNA) levels.
Case presentation
Case report
A 51 - year – old Caucasian female was admitted to our
Division of Hepatology because of chronic HCV infection.
She showed a little increase of serum glutamic oxaloacetic
transaminase (AST) and of serum glutamic pyruvic trans-
aminase (ALT) levels, approximately two times the upper
limit of the normal range, platelet count (PLT) about
132,000/mm3, absence of splenomegaly, anti-HCV posi-
tivity and positive serum HCV-RNA, genotype 3a. After
4 months, there was a decrease in platelet count (PLT
56.000/mm3) with a further increase in AST and ALT
levels. At physical examination there were no ecchimosis
or petechiae. Prothrombin time, albumin, pseudocholin-
esterase (PCHE) were all within the normal range. Ab-
dominal ultrasonography showed a liver with normal size
and moderate steatosis, portal vein of 10 mm and spleenFigure 1 Patient’s platelet count during pre-treatment and treatmentof 11.5 cm. The use of drugs potentially causing platelet
lysis was ruled out. Peripheral blood smear showed nor-
mal count of erythrocytes which were normochromic-
normocytic, normal leucocytes count, decreased platelet
count without platelet aggregates suggestive of a pseudo-
thrombocytopenia. Concomitant lymphoproliferative dis-
orders or autoimmune collagen vascular diseases were
excluded based on negative anti-nuclear antibodies, anti
mitochondrial antibodies, anti smoot-muscle antibodies,
anti-liver-kidney microsome antibodies, anti thyroid auto-
antibodies, antiphospholipid antibodies, cryoglobulins and
rheumatoid factor. Anti-platelet antibodies were found to
be positive and the diagnosis of HCV associated AITP was
reached. The patient started a corticosteroid therapy with
prednisone 1 mg/kg/die for the first month and with dose
tapering in the next three months until 5 mg/die. Platelet
count increased to 140,000/mm3 (Figure 1). The patient
continued steroid therapy with prednisone 5 mg/die.
Three months later platelet count was still close to
140,000/mm3 and the patient started therapy with PEG-
interferon-α2a and ribavirin 1200 mg/die. At the first
month she achieved a rapid virological response (RVR)
and the steroid therapy was discontinued. During antiviral
therapy, platelet count increased to over 200,000/mm3
and HCV-RNA was persistently undetectable. The patient
stopped the treatment after six months with a biochemical
and virological response and platelet count was till over
200,000/mm3. After one year of follow up patients is still
HCV-RNA negative and platelet count is 230,000/mm3.
Discussion
A number of autoimmune diseases, such as mixed es-
sential cryoblobulinemia, autoimmune hepatitis, systemic
lupus erythematosus (LES), glomerulonephritis, rheumatoidperiod.
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reported in association with HCV infection [17,18].
Chronic HCV infection has also been associated with the
development of autoimmune thrombocytopenic purpura
(AITP) in absence of overt liver disease. The prevalence of
autoimmune idiopathic thrombocytopenic pupura among
HCV-infected subjects is controversial [8,19-25]. The
overall incidence rate of AITP was higher among the
HCV-infected compared with the HCV uninfected sub-
jects. Also, the incidence rate of AITP was higher among
HCV infected patients who received treatment than in
HCV-infected subjects who did not. In our case, the
patient developed autoimmune thrombocytopenia while
she was not under treatment. After corticosteroids therapy
with subsequent normalization of platelet count, she
started standard antiviral therapy with PEG-interferon-
α2a and ribavirin. Platelet count increased, reaching ap-
proximately 200,000/100 ml. When at the first month of
antiviral therapy the HCV-RNA became negative, ste-
roids treatment was discontinued. Six months antiviral
therapy achieved a sustained biochemical and virological
response together with persistence of normal platelet
count, thus suggesting a causative role for HCV in AITP.
In further support of a pathogenic role for HCV in AITP,
a close relationship has been demonstrated between HCV
viral replication and thrombocytopenia. In particular, im-
provements in platelet count is generally associated with a
parallel decrease in HCV viral load [20,24,26] as in our
case. We observed a relationship between the decrease of
viral load during the treatment with PEG-interferon-α2a
and ribavirin and a further increase in platelet count dur-
ing antiviral treatment compared with steroid therapy
alone. The mechanism whereby HCV may cause AITP
is uncertain. HCV could determine an aberration of the
immune system resulting in the formation of anti-platelet
antibodies and/or immunocomplexes against platelet mem-
brane glycoproteins that bind to platelets leading to phago-
cytosis of them [22,26-28]. Another pathogenic mechanism
could include the specific binding between HCV and
human CD81 receptor on the platelet membrane, thus
causing autoantibody production against this complex
[29]. Finally, Chiao [25] hypothesized that HCV may
directly affect megacaryocytes thus causing their depletion.
There is some difference in the clinical picture between
HCV-related AITP and autoimmune idiopathic throm-
bocytopenia. Symptoms and sign of thrombocytopenia are
less frequent in HCV positive AITP, but major bleeding
is more frequent. Anticardiolipin antibodies and cryo-
globulins are more frequently detected in HCV-related
thrombocytopenia than in autoimmune idiopathic throm-
bocytopenia. In our case, the patient did not show any
symptoms related to thrombocytopenia such as ecchimo-
sis, petechiae, purpura or major bleeding, nor did she have
serum cryoglobulins or autoantibodies. Therapy of AITP,independently of HCV infection, is based on intravenous
immunoglobulin (IVIG) or anti-RhD Ig l [24,30,31]. While
IVIG was proven effective in increasing platelet counts in
90% of cases of HCV infected patients, this did not
achieve long-term response in this particular setting. Cor-
ticosteroid treatment for HCV-related AITP is controver-
sial. Three studies [21,23,24] have shown that response to
corticosteroids is significantly lower in HCV -positive than
in HCV-negative patients. On the other hand, some case
series of patients with HCV infection and chronic immune
thrombocytopenic purpura have reported a greater than
50% response to treatment [22,32,33]. In our case, the pa-
tient started prednisone 1 mg/kg/day for the first month
with tapering over the next three months. This led to an
increase in platelet count thus making it possible to then
start PEG-interferon-α2a plus ribavirin treatment. After
four weeks of antiviral therapy HCV-RNA became nega-
tive, steroid treatment discontinued and the platelet count
remained in the normal range during the six months of
antiviral therapy and after. Splenectomy is proposed as
second-line therapy. Zhang [23] and Sakuray [21] found
that response to splenectomy did not differ significantly
between the HCV-positive and HCV negative AITP pa-
tients. The role of antiviral therapy in HCV-related AITP
in not univocal. Approximately half of adult patients with
HCV-related AITP treated with interferon-α responded
with a rise in platelet count [34]. Also, Iga and colleagues
reported significant increase in the platelet count of 12
HCV- infected patients who were complete responders to
interferon-alpha treatment, but no improvement in the
platelet count of 11 patients who did not respond to
interferon-alpha therapy as assessed by viral load [35].
Also in our case, after the normalization of platelet count
with steroids, an antiviral treatment with PEG-interferon-
α2a and ribavirin was started with a significant sustained
increase in platelet count.
Conclusion
In our case report HCV seemed to play a pathogenic role
in AITP. We observed a close relationship between HCV
viral replication and thrombocytopenia. In particular,
improvements in platelet count is generally associated
with a parallel decrease in HCV viral load. We found also
a further increase in platelet count during antiviral treat-
ment compared with steroid therapy alone. Moreover in
our case the treatment schedule tapering simultaneously
steroids and standard antiviral therapy together with HCV-
RNA negativity was useful to revert thrombocytopenia.
Consent
Written informed consent was obtained from the patient
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